Learning Objectives:

  1. Understand the rationale for high-dose chemotherapy and autologous stem cell transplant (ASCT) in myeloma
  2. Review evidence of outcomes of ASCT compared to nonmyeloablative chemotherapy and modern triplet therapy.
  3. Discuss the optimal timing of ASCT in the overall treatment plan

and

Learning Objectives:

  1. To present the clinical rationale for biomarker use in checkpoint therapy of solid tumors
  2. To present the current clinical landscape and challenges of biomarker use in checkpoint therapy of solid tumors
  3. To present the landscape of investigational biomarkers to predict response to checkpoint therapy in solid tumors
Session date: 
Monday, June 25, 2018 - 12:00pm to 1:00pm
Speaker Name: 
Michael Leukam MD and Daniel Olson MD
Location: 
UCMC
5841 South Maryland Avenue
MC2115
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.